Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer

被引：30

作者：

Narita, Shintaro ^{[1
]}

Tsuchiya, Norihiko ^{[1
]}

Kumazawa, Teruaki ^{[2
]}

Maita, Shinya ^{[1
]}

Numakura, Kazuyuki ^{[1
]}

Obara, Takashi ^{[1
]}

Tsuruta, Hiroshi ^{[1
]}

Saito, Mitsuru ^{[1
]}

Inoue, Takamitsu ^{[1
]}

Horikawa, Yohei ^{[1
]}

Satoh, Shigeru ^{[1
]}

Nanjyo, Hiroshi ^{[3
]}

Habuchi, Tomonori ^{[1
]}

机构：

[1] Akita Univ, Sch Med, Dept Urol, Akita 010, Japan

[2] Senboku Gen Hosp, Dept Urol, Daisen, Japan

[3] Akita Univ, Sch Med, Dept Pathol, Akita 010, Japan

来源：

WORLD JOURNAL OF SURGICAL ONCOLOGY | 2012年 / 10卷

关键词：

chemohormonal therapy; prostate cancer; docetaxel; estramustine phosphate; complete androgen blockade; androgen deprivation; PHASE-II TRIAL; HORMONE-THERAPY; MITOXANTRONE; PREDNISONE;

D O I：

10.1186/1477-7819-10-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: To assess the outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with a high risk of localized prostate cancer (PCa). Methods: Complete androgen blockade followed by 6 cycles of docetaxel (30 mg/m(2)) with estramustine phosphate (560 mg) were given to 18 PCa patients before radical prostatectomy. Subsequently, the clinical and pathological outcomes were analyzed. Results: No patients had severe adverse events during chemohormonal therapy, and hence they were treated with radical prostatectomy. Two patients (11.1%) achieved pathological complete response. Surgical margins were negative in all patients. At a median follow-up of 18 months, 14 patients (77.8%) were disease-free without PSA recurrence. All 4 patients with PSA recurrence had pathologic T3b or T4 disease and 3 of these 4 patients had pathologic N1 disease. Conclusion: We found that neoadjuvant chemohormonal therapy with complete androgen blockade followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy was safe, feasible, and associated with favorable pathological outcomes in patients with a high risk of localized PCa.

引用

页数：6

共 19 条

[1] Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: Intermediate-term results [J].